Conjugate of c-di-GMP G-quadruplex inducer and NO donor and application of conjugate in antibacterial biofilm

By designing conjugates of c-di-GMP G-quadrimer inducer and NO donor, combined with antibiotic use, the problem of resistance of mature biofilms to antibiotics is solved, and the inhibition and dispersion of biofilms are achieved, which significantly improves the It provides dual-function antibiofilm drugs and adjuvants.

CN118930497APending Publication Date: 2024-11-12JINAN UNIVERSITY
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202310527268.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2023-05-11
Publication Date
2024-11-12

AI Technical Summary

Technical Problem

The problem of biofilm infection with existing antibiotic resistance, especially the resistance of mature biofilms to antibiotics, is difficult to overcome, resulting in patients being infected again after stopping the drug, and simple biofilm inhibitors cannot disperse mature biofilms.

Method used

Design a conjugate of c-di-GMP G-quadrimer inducer and NO donor to inhibit biofilm formation by inducing c-di-GMP to form G-quadrimers while releasing NO to disperse mature organisms Membrane, combined with antibiotics to improve bactericidal effect.

Benefits of technology

Effective inhibition and dispersion of mature biofilms has been achieved, significantly improving the bactericidal effect of antibiotics on bacteria in biofilms, providing dual-functional antibiofilm drugs and adjuvants, and overcoming the challenge of biofilm resistance.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118930497A_ABST
    Figure CN118930497A_ABST
Patent Text Reader

Abstract

The invention belongs to the field of medicines, and discloses a conjugate of a bacterial messenger molecule c-di-GMP G-quadruplex inducer and an NO donor as well as a preparation method and application of the conjugate. The structural formula of the conjugate is as shown in a formula I or II, 2-methylbenzothiazole or 2-methylquinoline is used as a lead compound for modification and transformation, a series of conjugates of benzothiazole or quinoline compounds and NO donors are designed, the synthesized conjugates can be used as G-quadruplex inducers capable of releasing NO gas, and the G-quadruplex inducers can be used for preparing G-quadruplex inducers capable of releasing NO gas. C-di-GMP is induced into a G quadruplex to inhibit biofilm formation and release NO gas to disperse a mature biofilm, the bifunctional antibacterial biofilm effect, especially the pseudomonas aeruginosa biofilm, is played, and the conjugate serves as an antibacterial adjuvant to enhance the bactericidal effect of antibiotics on bacteria forming the biofilm. # imgabs0 #
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of medicine, and particularly relates to a conjugate of a bacterial messenger molecule c-di-GMP G-quadruplex inducer and an NO donor, and its application as a dual-function anti-biofilm preparation based on inducing 3',5'-cyclic diguanosine (c-di-GMP) to form a functionally deficient G-quadruplex to inhibit biofilm formation and releasing NO to disperse mature biofilm. Background Art

[0002] Antibiotic resistance caused by biofilm infection, which is associated with more than 80% of chronic bacterial infections, has become a serious clinical problem. The concentration of antimicrobial agents used to kill bacteria in biofilms can be 10 to 1000 times higher than that of ordinary planktonic bacteria. However, no selective biofilm inhibitor has been successfully used in clinical practice so far. This may be because when bacterial infection is detected in actual clinical situations, part of the mature biofilm has already formed, and simple biofilm inhibitors can only inhibit biofilm formation, and cannot disperse the mature part of the biofilm, so that the bacteria in this part of the biofilm are protected from being killed by antibiotics. This is also a potential factor that causes patients to be infected again and cannot be cured after stopping medication. Therefore, the development of a dual-function anti-biofilm agent that has the ability to inhibit biofilm formation and disperse mature biofilms may be more likely to overcome clinical biofilm resistance.

[0003] It is reported that nitric oxide (NO) can destroy mature biofilms by reacting with free radicals. At the same time, NO can interact with receptor proteins such as NosP and NbdA present in the c-di-GMP synthesis / degradation enzyme operator, stimulate the activity of phosphodiesterase (PDE) responsible for the hydrolysis of the bacterial messenger molecule c-di-GMP to regulate the level of c-di-GMP, thereby inhibiting bacterial adhesion, aggregation and biofilm formation, and inducing the dispersion of bacterial biofilms. In recent years, people have increasingly realized that the level of bacterial second messenger 3',5'-cyclic diguanosine (c-di-GMP) has a more direct impact on the ability of bacteria to form biofilms. High c-di-GMP levels will induce bacteria to choose a group survival mode and significantly promote biofilm formation. However, the regulatory pathway of c-di-GMP is very complex, and the regulation of a single enzyme or receptor factor may not effectively reduce the level of c-di-GMP in bacteria. The latest research shows that c-di-GMP can be induced by planar aromatic small molecules into G-quadruplexes that have lost their biological functions, thereby reducing the effective level of c-di-GMP in bacteria and inhibiting the formation of bacterial biofilms. This may be a more effective strategy to inhibit the formation of bacterial biofilms. Summary of the invention

[0004] In order to overcome the shortcomings and deficiencies of the above-mentioned prior art, the primary purpose of the present invention is to provide a compound design strategy for a conjugate of a benzothiazole or quinoline compound and a nitric oxide (NO) donor, wherein the conjugate can release NO and disperse mature biofilms. After releasing NO, the G-quadruplex inducer can directly act on the signal molecule c-di-GMP itself, and indirectly reduce its effective concentration by inducing it to form a functionally deficient G-quadruplex, thereby affecting the phenotype related to the bacterial messenger molecule c-di-GMP, inhibiting the formation of bacterial biofilms, and having the potential to be developed into a bifunctional anti-biofilm drug.

[0005] Another object of the present invention is to provide a method for preparing the above conjugate.

[0006] Another object of the present invention is to provide the application of the above-mentioned conjugate in antibacterial biofilm. The c-di-GMP G quadruplex inducer and NO donor conjugate designed and synthesized by the present invention can inhibit biofilm formation by inducing c-di-GMP to form G quadruplexes while releasing NO to disperse mature biofilms, having a dual-effect anti-biofilm effect, and can improve the bactericidal effect of antibiotics on bacteria in biofilms, and has the potential to be developed into an anti-biofilm bacterial adjuvant.

[0007] The purpose of the present invention is achieved through the following solutions:

[0008] A conjugate of a bacterial messenger molecule c-di-GMP G-quadruplex inducer and an NO donor, having a structure shown in Formula I or II:

[0009]

[0010] The number of substitutions of R1 on the benzene ring is 1, 2 or more. When the number of substitutions of R1 on the benzene ring exceeds one, the substituents R1 may be the same or different; R1 is relatively independent of -H, -F, -Br, -NO2, -CH3, -NH2, -N(CH3)2, 4-methylpiperazine-1-yl, 4-morpholinyl, -OH or -OCH3;

[0011] The number of NO donors on the benzene ring can be 1, 2 or more. When the number exceeds 1, the NO donors can be the same or different. The NO donors are all relatively independent and are one of the following structural fragments, wherein when R2 is an alkyl group, the number of C atoms is 1-3:

[0012]

[0013] Preferably, the conjugate of the bacterial messenger molecule c-di-GMP G-quadruplex inducer and the NO donor has the following structure:

[0014]

[0015] The definitions of R1 and R2 therein are consistent with those of R1 and R2 in formula I and II.

[0016] More preferably, the conjugate of the bacterial messenger molecule c-di-GMP G-quadruplex inducer and the NO donor has the following structure:

[0017]

[0018] A method for preparing the above-mentioned conjugate comprises the following steps:

[0019] First, 2-methylbenzothiazole or 2-methylquinoline undergoes a methylation reaction with methyl iodide to obtain compound 4 or compound 6; benzaldehyde (i.e., compound 2) containing a halogen atom substituent and other substituents undergoes a nucleophilic substitution reaction with an aliphatic amine (R2-NH2) to obtain compound 5;

[0020] Then, compound 4 or compound 6 reacts with compound 5 to produce a benzothiazole compound A or a quinoline compound B;

[0021] Finally, A (or B) and NO gas react under high pressure to form a conjugate.

[0022] The preparation route is as follows:

[0023]

[0024] The definitions of R1 and R2 are consistent with those of R1 and R2 in formula I and II, and -X is one of -Br, -Cl, -F, and -I.

[0025] Preferably, the method for preparing the conjugate comprises the following steps:

[0026] (1) Dissolve 2-methylbenzothiazole or 2-methylquinoline in a solvent, add iodomethane, and then heat under reflux for 12 to 18 hours under a nitrogen atmosphere. After the reaction is completed, compound 4 or compound 6 is obtained;

[0027] (2) Compound 2 and fatty amine R2-NH2 are dissolved in a solvent, a catalyst is added, and then heated to react for 24 h to 48 h. After the reaction is completed, compound 5 is obtained;

[0028] (3) Compound 4 (or Compound 6) and Compound 5 are dissolved in a solvent, a catalyst is added, and then heated to reflux for reaction for 12 h to 16 h. After the reaction is completed, a benzothiazole compound A (or quinoline compound B) is obtained.

[0029] (4) using a solvent to completely dissolve compound A (or B), adding the solution to a high pressure reactor, and reacting with NO at room temperature under a pressure of 1 to 10 MPa for 12 to 72 hours, to obtain a conjugate A@NO (or B@NO) after the reaction is completed.

[0030] The molar ratio of 2-methylbenzothiazole or 2-methylquinoline to methyl iodide in step (1) is 1:1.05-1.5, preferably 1:1.2;

[0031] The solvent in step (1) is at least one of acetonitrile, ethanol, DMF and toluene. The solvent only serves as a reaction medium, so the amount of the solvent is not limited.

[0032] After the reaction in step (1) is completed, a purification step is also included. The purification refers to cooling the obtained reaction solution to room temperature and filtering it with suction, and then washing it with acetonitrile and diethyl ether to obtain compound 4 (or compound 6).

[0033] The solvent in step (2) is DMSO, the reaction container is a pressure-resistant thick-walled bottle, and the solvent cannot exceed 1 / 2 of the volume;

[0034] The catalyst described in step (2) is copper powder or tetrabutylammonium bromide and potassium carbide; when the catalyst is copper powder, the molar ratio of compound 2, fatty amine and copper powder described in step (2) is 1:6-10:0.02-0.05; when the catalyst is tetrabutylammonium bromide and potassium carbide, the molar ratio of compound 2, fatty amine, tetrabutylammonium bromide and potassium carbonate described in step (2) is 1:5-6:0.1-0.5:0.5-1.

[0035] The temperature of the heating reaction in step (2) is 98-102°C;

[0036] After the reaction in step (2) is completed, a purification step is also included, wherein the purification refers to using petroleum ether:ethyl acetate = 50:1 to perform rapid column chromatography to remove unreacted raw materials.

[0037] The solvent in step (3) is at least one of methanol and ethanol. The solvent only serves as a reaction medium, so the amount of the solvent is not limited.

[0038] The catalyst described in step (3) is piperidine or pyridine;

[0039] The molar ratio of compound 4 (or compound 6), compound 5 and catalyst in step (3) is 1:1.1-1.5:0.1-0.5;

[0040] After the reaction of step (3) is completed, a purification step is also included. The purification refers to cooling the obtained reaction solution to room temperature and filtering it with suction, and then washing it with methanol or ethanol or diethyl ether. If further purification is required, it is recrystallized with methanol or diethyl ether.

[0041] The solvent in step (4) is one or two of acetonitrile, methanol, and ethanol. The solvent only serves as a reaction medium, so the amount of the solvent is not limited.

[0042] The high-pressure reactor used in step (4) needs to first replace the air with nitrogen and then replace the nitrogen with nitric oxide.

[0043] After the reaction of step (4) is completed, a purification step is also included, wherein the purification refers to filtering the reaction solution, then washing with methanol, ethanol or ether, and if further purification is required, recrystallizing with methanol or ether. The reaction product is photosensitive, so be careful to avoid light during post-processing.

[0044] The conjugate of the bacterial messenger molecule c-di-GMP G-quadruplex inducer and the NO donor is used in the preparation of antibacterial biofilm drugs and as an antibacterial adjuvant, especially in the preparation of Pseudomonas aeruginosa biofilm inhibitors.

[0045] The antibacterial biofilm drug contains at least one of the conjugate of the bacterial messenger molecule c-di-GMP G-quadruplex inducer and NO donor described in the present invention, the pharmaceutically acceptable salt of the conjugate described in the present invention, and the solvate of the conjugate described in the present invention. It is well known that the solvated form and salt of a compound generally do not affect the biological activity of the compound itself.

[0046] The antibacterial biofilm drug may contain one or more pharmaceutically acceptable carriers or excipients.

[0047] The application as an anti-biofilm bacterial adjuvant refers to the combined use of the conjugate and an antibiotic, wherein the antibiotic is preferably tobramycin, the concentration of the conjugate is greater than or equal to the effective concentration for removing biofilm (preferably 1.25μM to 10μM), and the concentration of the antibiotic is greater than or equal to the minimum bactericidal concentration (MBC), preferably 8μg / mL.

[0048] Compared with the prior art, the present invention has the following advantages and beneficial effects:

[0049] (1) The present invention synthesizes conjugates of benzothiazole or quinoline compounds and nitric oxide donors and applies them to the development of antibacterial biofilm drugs. The conjugate A11@NO is the first successfully synthesized conjugate of c-di-GMP G quadruplex inducer and NO donor.

[0050] (2) Compared with the simple c-di-GMP G quadruplex inducer, A11@NO has better inhibitory activity against bacterial biofilms and has the ability to remove mature biofilms. In addition, when used in combination with antibiotics, it can significantly enhance the bactericidal effect of antibiotics against bacteria that have already formed biofilms. It is a good adjuvant for anti-biofilm bacteria. BRIEF DESCRIPTION OF THE DRAWINGS

[0051] Figure 1 Circular dichroism spectral data of compounds A1, A2, A3, A4, A11, B1, B2, B3 and negative control;

[0052] Figure 2 The biofilm inhibition rate of compounds A1, A2, A3, A4, B1, B2, and B3 at the optimal concentration of 2.5 μM;

[0053] Figure 3 Comparison of biofilm inhibition rates of compound A11 and conjugate A11@NO in the concentration range of 0.625-5 μM;

[0054] Figure 4 The amount of biofilm remaining after 0.625-40 μM conjugate A11@NO acted on mature biofilm for 15 h;

[0055] Figure 5 The residual biofilm amount after 0.625-40 μM compound A11 acted on mature biofilm for 15 h;

[0056] Figure 6 The amount of bacteria that have formed mature biofilms after being treated with different concentrations of conjugates and MBC tobramycin for 15 h;

[0057] Figure 7 Survival rate of nematodes in biofilm environment containing different concentrations of conjugate and MBC tobramycin within 3 h. DETAILED DESCRIPTION

[0058] The present invention is further described in detail below in conjunction with examples and drawings, but the embodiments of the present invention are not limited thereto.

[0059] Unless otherwise specified, the reagents used in the examples can be purchased from the market. The bacteria used in Example 18 and subsequent examples: Pseudomonas aeruginosa PAO1-ΔwspF, the construction method of which has been disclosed in the literature [Jason W.Hickman.et al., A chemosensory system that regulates biofilm formation through modulation of cyclic diguanylate levels. PNAS, 2005.102(40): p.14422-14427]. PAO1-ΔwspF represents the knockout of the wspF gene in PAO1 bacteria. Although PAO1-ΔwspF does not appear in the literature, the Result on page 14423 of the reference discloses "To investigate the function of the wsp gene cluster in P.aeruginosa, in-frame deletions of wspA, wspE, wspF, and wspR were constructed (Fig. 1, see Materials and Methods), therefore, the wspF gene, namely ΔwspF in the literature, was knocked out in PAO1 bacteria, and the present invention named it PAO1-ΔwspF.

[0060] Example 1: Synthesis of 2,3-dimethylbenzo[d]thiazole-3-iodide (Synthesis of Compound 4)

[0061] 2-Methylbenzothiazole (7.13 mL, 56 mmol) was dissolved in MeCN (80 mL). Methyl iodide (5.6 mL, 84 mmol) was added to the solution. The mixture was then heated to reflux under N2 for 15 hours. After cooling, the resulting precipitate was filtered and then washed with MeCN and Et2O to obtain 12.78 g of a white solid with a yield of 78%. 1 H NMR (400MHz, DMSO) δ8.47(d,J=8.1Hz,1H),8.29(d,J=8.5Hz,1H),7.88(t,J=7.8Hz,1H),7.79(t,J=7.7Hz,1H),4.22(s,3H),3.20(s,3H). 13 C NMR (101MHz, DMSO) δ177.09,141.51,129.19,128.62,127.98,124.48,116.73,36.43,17.43.ESI-MS(m / z):164[MI] + .

[0062] Example 2: Synthesis of 1,2-dimethylquinoline-1-iodide (Synthesis of Compound 6)

[0063] Iodomethane (5.6 mL, 84 mmol) was added to a solution of 2-methylquinoline (7.2 mL, 56 mmol) in MeCN (80 mL). The mixture was then heated to reflux under N2 for 15 hours. After cooling, the resulting precipitate was filtered and then washed with MeCN and Et2O to give 13.36 g of a green solid. Yield 84%. 1 H NMR (400MHz, DMSO) δ9.11(d,J=8.6Hz,1H),8.59(d,J=9.0Hz,1H),8.40(d,J=8.0Hz,1H),8 .27–8.18(m,1H),8.13(d,J=8.6Hz,1H),7.98(t,J=7.6Hz,1H),4.46(s,3H),3.10(s,3H). 13 C NMR (101MHz, DMSO) δ161.11,145.32,139.13,135.01,130.24,128.94,127.72,125.10,118.98,39.88,23.24.

[0064] Example 3: Synthesis of 4-methylamino-benzaldehyde (Synthesis of Compound 5)

[0065] 4-Bromobenzaldehyde (2.22 g, 12 mmol), tetrabutylammonium bromide (388 mg, 1.2 mmol), K2CO3 (825 mg, 6 mmol), methylamine (2.1 mL, 60 mmol) were added to 10 mL DMSO, the tube was sealed, and heated at 98 ° C for 36 hours; the mixture was cooled to room temperature, diluted with 30 mL of water, and extracted with ethyl acetate (50 mL x 4). The combined organic phase was washed with water (30 mL) and brine (30 mL), and the organic phase was dried over anhydrous Na2SO4. After filtering, the mixture was concentrated in vacuo to obtain a crude product. The product was separated and purified by rapid column chromatography; after concentration, 535 mg of brown oil was obtained. Yield: 33%. 1 HNMR (400MHz, CDCl3) δ9.73 (s, 1H), 7.71 (d, J = 8.7Hz, 2H), 6.61 (d, J = 8.7Hz, 2H), 2.93 (s, 3H). 13 C NMR (101MHz, CDCl3) δ190.49,154.44,132.41,126.32,111.55,30.08,1.10.

[0066] Example 4: Synthesis of 4-ethylamino-benzaldehyde (Synthesis of Compound 5)

[0067] 4-Bromobenzaldehyde (0.654mL, 6mmol), tetrabutylammonium bromide (969mg, 3mmol), K2CO3 (825mg, 6mmol), ethylamine (3mL, 36mmol) were added to 10mL DMSO, the tube was sealed, and heated at 98°C for 36 hours; the mixture was cooled to room temperature, diluted with 30mL water, and extracted with ethyl acetate (50mL x4). The combined organic phase was washed with water (30mL) and brine (30mL), and the organic phase was dried over anhydrous Na2SO4. After filtration, the mixture was concentrated in vacuo to obtain a crude product. The product was separated and purified by rapid column chromatography; after concentration, 278 mg of a brown solid was obtained. Yield: 29%. 1H NMR (400MHz, CDCl3) δ9.70 (s, 1H), 7.67 (d, J = 8.6Hz, 2H), 6.58 (d, J = 8.6Hz, 2H), 4.46 (s, 1H), 3.23 (q, J = 7.2Hz ,2H),1.27(t,J=7.2Hz,3H).13CNMR(101MHz,CDCl3)δ190.34,153.53,132.43,126.30,111.76,37.90,14.56.

[0068] Example 5: Synthesis of 4-propylamino-benzaldehyde (Synthesis of Compound 5)

[0069] 4-Bromobenzaldehyde (2.22 g, 12 mmol), tetrabutylammonium bromide (388 mg, 1.2 mmol), K2CO3 (825 mg, 6 mmol), and n-propylamine (5.91 mL, 72 mmol) were added to 10 mL of DMSO, sealed, and heated at 98 ° C for 36 hours; the mixture was cooled to room temperature, diluted with 30 mL of water, and extracted with ethyl acetate (50 mL x 4). The combined organic phase was washed with water (30 mL) and brine (30 mL), and the organic phase was dried over anhydrous Na2SO4. After filtration, the mixture was concentrated in vacuo to obtain a crude product. The product was separated and purified by rapid column chromatography; after concentration, 353 mg of dark brown oil was obtained. Yield: 18%. 1 H NMR (400MHz, CDCl3) δ9.72(s,1H),7.69(d,J=8.6Hz,2H),6.60(d,J=8.6Hz,2H),3.18(t,J=7.1Hz,2H),1.73–1.63(m,2H),1.02(t,J=7.4Hz,3H).

[0070] Example 6: Synthesis of 4-isopropylamino-benzaldehyde (Synthesis of Compound 5)

[0071] 4-Bromobenzaldehyde (2.22 g, 12 mmol), tetrabutylammonium bromide (388 mg, 1.2 mmol), K2CO3 (825 mg, 6 mmol), isopropylamine (5.14 mL, 60 mmol) were added to 10 mL of DMSO, the tube was sealed, and heated at 98 ° C for 36 hours; the mixture was cooled to room temperature, diluted with 30 mL of water, and extracted with ethyl acetate (50 mL x 4). The combined organic phase was washed with water (30 mL) and brine (30 mL), and the organic phase was dried over anhydrous Na2SO4. After filtering, the mixture was concentrated in vacuo to obtain a crude product. The product was separated and purified by rapid column chromatography; after concentration, 196 mg of an orange-yellow oil was obtained. Yield: 10%. 1 H NMR (400MHz, CDCl3) δ9.70(s,1H),7.68(d,J=8.6Hz,2H),6.57(d,J=8.7Hz,2H),4.21(s,1H),3.78–3.66(m,1H),1.25(d,6H). 13 C NMR (101MHz, DMSO) δ171.01,150.67,146.39,145.22,141.90,129.91,128.76,127. 25,126.61,123.67,121.55,115.74,108.63,107.97,105.52,56.01,35.61,29.24.

[0072] Example 7: Synthesis of 4-methylamino-3-methoxy-benzaldehyde (Synthesis of Compound 5)

[0073] 4-Bromo-3-methoxybenzaldehyde (430mg, 2mmol), copper powder (3.813mg, 0.06mmol), methylamine (2.353mL, 20mmol) were added to 2mL DMSO, sealed, and heated at 100°C for 48 hours. The mixture was cooled to room temperature; the mixture was diluted with 30mL water and extracted with ethyl acetate (50mL x4). The combined organic phase was washed with water (30 ml) and brine (30 ml), and the organic phase was dried over anhydrous Na2SO4. After filtration, the mixture was concentrated in vacuo to obtain a crude product. The product was separated and purified by rapid column chromatography; after concentration, 276mg of an orange oil was obtained, with a yield of 84%. 1H NMR (400MHz, CDCl3) δ9.69(s,1H),7.38(dd,J=8.1,1.4Hz,1H),7.26(d,J=1.3Hz,1H),6.56(d,J=8.1Hz,1H),3.88(s,3H),2.93(s,3H). 13 C NMR (101MHz, CDCl3) δ190.30,146.34,145.14,129.10,125.36,106.76,106.19,55.38,29.45.

[0074] Example 8: Synthesis of (E)-2-(4-methylaminophenylvinyl)-3-methylbenzo[d]thiazole-3-iodide (Synthesis of Compound A1)

[0075] Compound 4 (2 mmol) and 4-methylamino-benzaldehyde (2.4 mmol) were placed in a 25 mL round-bottom flask, 5 mL of methanol was added, and then piperidine solution (0.2 mmol) was added dropwise. The mixture was reacted at 65°C overnight, cooled to room temperature, filtered, and the filter cake was washed with cold methanol to obtain green powder A1. Yield: 36%. mp247.6-249.2°C. 1 H NMR (400MHz, DMSO) δ8.28(d,J=8.0Hz,1H),8.05(dd,J=20.5,11.8Hz,2H),7.85(d,J=8.7Hz,2H),7.77(t,J=7.8Hz,1H),7.6 7(t,J=7.7Hz,1H),7.56(d,J=15.3Hz,1H),7.24(d,J=5.0Hz,1H),6.69(d,J=8.7Hz,2H),4.20(s,3H),2.83(d,J=5.0Hz,3H); 13 C NMR(101MHz,DMSO)δ171.18,154.44,150.37,141.88,133.28,128.78,127.30,126.6 5,123.73,121.54,115.81,111.99,105.47,35.54,29.17.HRMS(m / z):281.1096[MI] + ,calcd for C 17 H 17 N2S,281.1107.

[0076] Example 9: Synthesis of (E)-2-(4-ethylaminophenylvinyl)-3-methylbenzo[d]thiazole-3-iodide (Synthesis of Compound A2)

[0077] Compound 4 (2 mmol) and 4-ethylamino-benzaldehyde (2.4 mmol) were placed in a 25 mL round-bottom flask, 5 mL of methanol was added, and then piperidine solution (0.2 mmol) was added dropwise. The mixture was reacted at 65°C overnight, cooled to room temperature, filtered, and the filter cake was washed with cold methanol to obtain yellow powder A2. Yield: 41%. mp257.8-258.2°C. 1 H NMR (400MHz, DMSO) δ8.27(d,J=7.6Hz,1H),8.07(d,J=8.4Hz,1H),8.01(d,J=15.2Hz,1H),7.84(d,J=8.7Hz,2H),7.80–7.72(m,1H),7.66(t ,J=7.7Hz,1H),7.54(d,J=15.2Hz,1H),7.21(t,J=5.3Hz,1H),6.70(d,J=8.8Hz,2H),4.20(s,3H),3.25–3.16(m,2H),1.20(t,J=7.2Hz,3H); 13 C NMR(101MHz,DMSO)δ172.34,157.99,143.47,142.04,134.30,129.74,129.32,128.26,12 7.53,124.19,120.69,119.80,116.79,116.56,112.81,36.37.HRMS(m / z):295.1251[MI] + ,calcd forC 18 H 19 N2S,295.1266.

[0078] Example 10: Synthesis of (E)-2-(4-propylaminophenylvinyl)-3-methylbenzo[d]thiazole-3-iodide (Synthesis of Compound A3)

[0079] Compound 4 (2 mmol) and 4-propylamino-benzaldehyde (2.4 mmol) were placed in a 25 mL round-bottom flask, 5 mL of methanol was added, and then piperidine solution (0.2 mmol) was added dropwise. The mixture was reacted at 65°C overnight, cooled to room temperature, filtered, and the filter cake was washed with cold methanol to obtain a purple powder A3. Yield: 19%. mp228.3-229.1°C. 1H NMR (400MHz, DMSO) δ8.28(d,J=8.0Hz,1H),8.05(dd,J=24.0,11.8Hz,2H),7.84(d,J=8.8Hz,2H),7.82–7.74(m,1H),7.67(t,J=7.7Hz,1H),7.56(t ,J=10.4Hz,1H),7.26(t,J=5.5Hz,1H),6.73(d,J=8.9Hz,2H),4.21(s,3H ),3.16(dd,J=12.9,6.6Hz,2H),1.64–1.55(m,2H),0.97(t,J=7.4Hz,3H); 13 CNMR(101MHz,DMSO)δ171.09,153.82,150.31,141.87,133.33,128.75,127.25,126.61, 123.71,121.44,115.77,105.28,44.05,35.51,21.75,11.54.HRMS(m / z):309.1406[MI] + ,calcd for C 19 H 21 N2S,309.1420.

[0080] Example 11: Synthesis of (E)-2-(4-isopropylaminophenylvinyl)-3-methylbenzo[d]thiazole-3-iodide (Synthesis of Compound A4)

[0081] Compound 4 (2 mmol) and 4-isopropylamino-benzaldehyde (2.4 mmol) were placed in a 25 mL round-bottom flask, 5 mL of methanol was added, and then piperidine solution (0.2 mmol) was added dropwise. The mixture was reacted at 65°C overnight, cooled to room temperature, filtered, and the filter cake was washed with cold methanol to obtain a purple-black powder A4 with a yield of 17%. mp239.1-240.3°C. 1 H NMR (400MHz, DMSO) δ8.28(d,J=8.0Hz,1H),8.07(d,J=8.4Hz,1H),8.01(d,J=15.2Hz,1H),7.84(d,J=8.8Hz,2H),7.80–7.73(m,1H),7.67(t,J=7. 7Hz,1H),7.54(d,J=15.2Hz,1H),7.12(d,J=7.8Hz,1H),6.72(d,J=8.9Hz,2H),4.20(s,3H),3.78(dq,J=12.8,6.5Hz,1H),1.19(t,J=6.5Hz,6H); 13C NMR(101MHz,DMSO)δ171.09,152.89,150.31,141.87,133.38,128.73,127.22,126.58,1 23.69,121.31,115.74,112.36,105.21,43.20,35.44,22.20.HRMS(m / z):309.1407[MI] + ,calcd for C 19 H 21 N2S,309.1420.

[0082] Example 12: Synthesis of (E)-2-(3-methoxy-4-methylaminophenylvinyl)-3-methylbenzo[d]thiazole-3-iodide (Synthesis of Compound A11)

[0083] Compound 4 (2 mmol) and 4-methylamino-3-methoxy-benzaldehyde (2.4 mmol) were placed in a 25 mL round-bottom flask, 5 mL of methanol was added, and then pyridine solution (1 mmol) was added dropwise. The mixture was reacted at 65°C overnight, cooled to room temperature, filtered, and the filter cake was washed with cold methanol to obtain a purple powder A11 with a yield of 93%. mp 238.2-240.1°C. 1 H NMR (400MHz, DMSO) δ8.28(d,J=8.1Hz,1H),8.03(dd,J=20.2,11.8Hz,2H),7.76(t,J=7.8Hz,1H),7.65(t,J=7.7Hz,1H) ,7.54(dd,J=20.4,12.9Hz,3H),6.73(s,1H),6.59(d,J=8.4Hz,1H),4.22(d,J=11.6Hz,3H),3.94(s,3H),2.84(s,3H). 13 C NMR(101MHz,DMSO)δ171.01,150.67,146.39,145.22,141.90,129.91,128.76,127.25,126.61,1 23.67,121.55,115.74,108.63,107.97,105.52,56.01,35.61,29.24.HRMS(m / z):311.1202[MI] + ,calcd for C 18 H 19 ON2S,311.1213.

[0084] Example 13: Synthesis of (E)-2-(4-methylaminophenylvinyl)-1-methylquinoline-1-iodide (Synthesis of Compound B1)

[0085] Compound 6 (2 mmol) and 4-methylamino-benzaldehyde (2.4 mmol) were placed in a 25 mL round-bottom flask, 5 mL of methanol was added, and then piperidine solution (0.2 mmol) was added dropwise. The mixture was reacted at 65°C overnight, cooled to room temperature, filtered, and the filter cake was washed with cold methanol to obtain a green powder B1 with a yield of 45%. mp 245.2-247.1°C. 1 H NMR (400MHz, DMSO) δ8.78(d,J=9.1Hz,1H),8.49(d,J=9.2Hz,1H),8.41(d,J=9.0Hz,1H),8.26–8.21(m,2H),8.08(t,J=8.0Hz,1H),7. 82(dd,J=15.5,8.1Hz,3H),7.50(d,J=15.4Hz,1H),6.99(d,J=5.0Hz,1H),6.69(d,J=8.7Hz,2H),4.43(s,3H),2.82(d,J=5.0Hz,3H); 13 C NMR (101MHz, DMSO) δ156.30,153.65,149.26,141.61,139.16,134.03,132.41,129.73,127.8 6,126.65,122.44,120.11,118.73,111.77,111.00,38.95,29.19.HRMS(m / z):275.1531[MI] + ,calcd forC 19 H 19 N2,275.1543

[0086] Example 14: Synthesis of (E)-2-(4-ethylaminophenylvinyl)-1-methylquinoline-1-iodide (Synthesis of Compound B2)

[0087] Compound 6 (2 mmol) and 4-ethylamino-benzaldehyde (2.4 mmol) were placed in a 25 mL round-bottom flask, 5 mL of methanol was added, and then piperidine solution (0.2 mmol) was added dropwise. The mixture was reacted at 65°C overnight, cooled to room temperature, filtered, and the filter cake was washed with cold methanol to obtain a green powder B2 with a yield of 36%. mp 247.1-248.6°C. 1H NMR (400MHz, DMSO) δ8.77(d,J=9.0Hz,1H),8.50(d,J=9.2Hz,1H),8.41(d,J=8.9Hz,1H),8.27–8.19(m,2H),8.06(t,J=7.8Hz,1H),7.81(dd,J=15. 9,8.1Hz,3H),7.48(d,J=15.5Hz,1H),6.70(d,J=8.5Hz,2H),4.42(s,3H) ,3.35–3.35(m,1H),3.18(dd,J=14.2,7.1Hz,2H),1.19(t,J=7.1Hz,3H); 13 CNMR(101MHz,DMSO)δ156.25,152.79,149.23,141.53,139.14,133.99,132.45,129.70,127. 81,126.61,122.39,120.09,118.70,111.92,110.88,36.93,14.11.HRMS(m / z):289.1686[MI] + ,calcd for C 20 H 21 N2,275.1699.

[0088] Example 15: Synthesis of (E)-2-(4-propylaminophenylvinyl)-1-methylquinoline-1-iodide (Synthesis of Compound B3)

[0089] Compound 6 (2 mmol) and 4-propylamino-benzaldehyde (2.4 mmol) were placed in a 25 mL round-bottom flask, 5 mL of methanol was added, and then piperidine solution (0.2 mmol) was added dropwise. The mixture was reacted at 65°C overnight, cooled to room temperature, filtered, and the filter cake was washed with cold methanol to obtain a bright green powder B3 with a yield of 54%. mp221.9-223.8°C. 1 H NMR (400MHz, DMSO) δ8.76(d,J=9.2Hz,1H),8.48(d,J=9.3Hz,1H),8.40(d, J=9.0Hz,1H),8.25–8.19(m,2H),8.10–8.01(m,1H),7.84–7.75(m,3H),7.4 6(d,J=15.4Hz,1H),6.98(t,J=5.5Hz,1H),6.70(d,J=8.8Hz,2H),4.41(s,3 H),3.11(dd,J=12.8,6.8Hz,2H),1.65–1.54(m,2H),0.96(t,J=7.4Hz,3H); 13C NMR(101MHz,DMSO)δ156.30,153.04,149.27,141.55,139.19,134.02,132.50,129.73,127.84,1 26.63,122.35,120.10,118.72,111.97,110.84,44.09,21.79,11.58.HRMS(m / z):303.1844[MI] + ,calcd for C 21 H 23 N2,303.1856.

[0090] Example 16: (E)-2-(4-Methyl(nitroso)aminophenylvinyl)-1-methylquinoline-1-iodide (Synthesis of Conjugate A11@NO)

[0091] Compound A11 (500 mg) was dissolved in a mixed solution of acetonitrile:methanol = 1:1 (volume ratio) (20 ml), and reacted with 1 MPa NO gas for 3 days, then filtered, and the filter cake was washed with methanol or acetonitrile to obtain a light brown powder with a yield of 43%. mp183.7 -185.5℃. 1 H NMR (400MHz, DMSO) δ8.48(d,J=7.9Hz,1H),8.29(dd,J=12.2,3.7Hz,2H),8.16(d,J=15.9Hz,1H),7.94–7. 89(m,2H),7.84(t,J=7.9Hz,2H),7.63(d,J=8.1Hz,1H),4.41(d,J=5.7Hz,3H),4.00(s,3H),3.34(s,3H). 13 C NMR (101MHz, DMSO) δ171.50,152.75,146.96,141.88,135.68,133.14,129.34,128.43,127.86,1 26.65,124.15,122.47,116.84,115.01,113.08,56.36,36.53,34.62.HRMS(m / z):340.1104[MI] + ,calcd forC 18 H 18 O2N3S,340.1114.

[0092] Example 17: Determination of c-di-GMP G-quadruplex-inducing activity of benzothiazole or quinoline compounds

[0093] The structure of the conjugates A@NO and B@NO of the present invention determines that after releasing NO, the remaining part is the prototype G-quadruplex inducer, so we only need to confirm whether the prototype compound has c-di-GMP G-quadruplex inducing activity.

[0094] Circular dichroism (CD) spectroscopy was used to screen and evaluate the ability of compounds to induce c-di-GMP to form G-quadruplexes (positive absorption peak at around 300 nm). The specific operation method is as follows: c-di-GMP was dissolved in 10mM Tris-HCl buffer solution (pH 7.5, containing 250mM KCl), heated to 95°C and kept at 95°C for 5 minutes, then slowly cooled to room temperature and kept at room temperature for 15 minutes, and then the test compound was added and mixed and incubated in a refrigerator at -20°C overnight (about 12 hours) to obtain a test solution. The concentration of c-di-GMP in the test solution was 70μM, the concentration of the test compound was 30μM, and the concentration of KCl was 250mM. The measurement was carried out at 25°C. At the same time, thiazole orange (TO) was used as a positive control, and no compound was added as a negative control. The results are as shown in the figure. Figure 1 As shown, compounds A1, A2, A3, A4, A11, B1, B2, B3, etc. all showed positive absorption peaks at around 300 nm, indicating that these compounds can induce c-di-GMP to form G-quadruplexes.

[0095] Example 18: Biofilm Inhibitory Activity Assay of Compounds

[0096] The crystal violet staining method was used to determine the biofilm inhibition activity of the compounds. The specific operation method was as follows: first, the test compound was diluted with LB medium to an optimal concentration of 2.5 μM as a drug solution for later use; Pseudomonas aeruginosa PAO1-ΔwspF (a strain constructed by Professor Yang Liang's research group from the Center for Environmental Life Science Engineering, Nanyang Technological University, Singapore, cultured in LB medium and stored at -80°C) was diluted with LB medium to OD 600 =0.01 as bacterial solution for standby use; then add 50 μL of drug solution and 50 μL of bacterial solution to each well of the 96-well plate, and set up a negative control group (only add 50 μL of bacterial solution and 50 μL of culture medium), and seal the edges with 100 μL of culture medium to prevent edge effects caused by volatilization and serve as a blank control without adding bacterial solution and drugs, and set up 6 duplicate wells; wrap the 96-well plate with plastic wrap or seal the edges with sealing film, and place it at 37°C for 24 hours; gently suck away the bacterial solution with a gun, wash it with PBS for 3 times, and blow it dry; add methanol to each well and fix it at room temperature for 20 minutes; suck away the methanol, blow it dry, add the filtered 0.1wt% crystal violet to dye for 15 minutes; suck away the dye, add PBS to wash three times; after blowing dry, add 33wt% glacial acetic acid to dissolve the crystal violet, and measure OD 570The OD value indirectly reflects the content of biofilm. The biofilm inhibition rate of the compound is calculated according to the following formula (control refers to the negative control group, blank refers to the blank control group):

[0097] Biofilm inhibition rate = [(control OD570 -blank OD570 )-(Drug Addition Group OD570 -blank OD570 )] / (control OD570 -blank OD570 )×100%

[0098] The results are as follows Figure 2 As shown, it can be seen that the benzothiazole and quinoline compounds prepared by the present invention have certain biofilm inhibition activity and can be used as precursor molecules for coupling NO donors.

[0099] Example 19: Comparison of anti-biofilm activity of conjugate A11@NO and its precursor molecule A11

[0100] The biofilm inhibition activity test method was the same as in Example 18, and the results were as follows Figure 3 As shown;

[0101] The specific experimental method of the biofilm removal activity test is as follows: 100 μL of the LB medium was added to each well of a 96-well plate to a concentration of OD 600 =0.02 overnight cultured bacterial solution, the edge wells were sealed with 200μL LB medium to prevent edge effect caused by volatilization, and placed in a 37℃ incubator for 24h; the upper bacterial solution was carefully sucked out with a spray gun, trying not to touch the bottom and side walls of the wells, and then 150μL PBS was used to wash away the residual floating bacteria in each well. During the operation, it was noted to tap and suck gently; A11 or A11@NO was diluted with PBS to the corresponding concentration, and 120μL of each well was added to the 96-well plate, and placed in a 37℃ incubator for 15h; the bacterial solution was gently sucked away with a gun, washed with PBS three times, and blown dry; methanol was added to each well and fixed at room temperature for 20min; the methanol was sucked away, and after blowing dry, filtered 0.1wt% crystal violet was added to dye for 15min; the dye was sucked away, and PBS was added to wash three times; after blowing dry, 33wt% glacial acetic acid was added to dissolve the crystal violet, and OD was measured. 570 The OD value indirectly reflects the content of biofilm. The results are as follows Figure 4 (A11@NO), Figure 5 (A11)

[0102] The biofilm clearance rate of the compound was calculated according to the following formula:

[0103] Biofilm removal rate = [(controlOD570 -blank OD570 )-(Drug Addition Group OD570 -blank OD570 )] / (control OD570 -blank OD570 )×100%

[0104] The experimental results show that at all tested concentrations, the biofilm inhibition rate of the conjugate A11@NO is higher than that of its precursor, the c-di-GMP G quadruplex inducer A11, especially when the concentration of A11@NO is 5μM, its biofilm inhibition rate can reach 76.4±9.0%, while compound A11 can only inhibit the formation of 55.6±7.7% of biofilm at most, indicating that NO and c-di-GMP G quadruplex inducer have a synergistic effect in inhibiting biofilm formation after coupling; the conjugate A11@NO has a good biofilm removal ability in the concentration range of 1.25μM-5μM, and even at a relatively low concentration of 1.25μM, it can reduce the amount of mature biofilm by 40-50%. However, compound A11 has no ability to remove mature biofilm at all, and there is no significant difference in the amount of biofilm between the drug-added group and the non-drug-added group.

[0105] Example 20: The bactericidal effect of the conjugate A11@NO and tobramycin on bacteria that have formed biofilms.

[0106] Add 100 μL of the diluted LB medium to each well of a 96-well plate to a concentration of OD 600 =0.02 overnight cultured bacterial solution, the edge wells were sealed with 200μL LB medium to prevent edge effect caused by volatilization, and placed in a 37℃ incubator for 24h; carefully aspirate the upper bacterial solution with a spray gun, trying not to touch the bottom and side walls of the wells, and then use 150μL PBS per well to wash away the remaining floating bacteria. Be careful to tap and aspirate gently during the operation; dilute the conjugate A11@NO to the corresponding concentration with LB medium containing 8μg / mL tobramycin, and then add it to a 96-well plate at a volume of 120μL per well, set up 4 replicates, and set the drug-containing culture medium without the conjugate as the control group, and place it in a 37℃ incubator for 15h before taking it out. Aspirate the bacterial solution and dilute it with sterile PBS, then apply it to the plate, place the plate in a 37℃ incubator for 16-24h, and then count the colonies, and calculate the bacterial survival rate compared with the control group. The results are as follows Figure 6 shown.

[0107] The experimental results show that when the conjugate A11@NO and MBC tobramycin are used in combination, the survival of biofilm bacteria within 15 hours is reduced by nearly 1000 times compared with the use of tobramycin alone.

[0108] Example 21: Survival rate of nematodes in mature biofilms under the action of conjugate A11@NO and tobramycin.

[0109] Synchronized Caenorhabditis elegans were grown to the L4 stage on Escherichia coli OP50 in nematode growth medium (NGM) agar (eggs were incubated at 25°C for 72 hours) and collected using OGM medium (95% M9 buffer, 5% brain heart perfusion solution, 10 μg / mL cholesterol, 200 μM 5-fluoro-2′-deoxyuridine). Healthy nematodes were divided into 20-40 / group, each group was in LB medium (supplemented with 200 μM 5-fluoro-2′-deoxyuridine) containing 8 μg / mL tobramycin (MBC concentration) and different concentrations (0, 1.25, 2.5, 5, 10 μM) of A11@NO, and then the grouped nematodes were inoculated on the 24-hour mature biofilm established as described above. 3 h after exposure, the live (curled / moving) and dead (straight / immovable) nematodes were counted under a microscope, and the survival rate was the ratio of live nematodes to the total number of nematodes in the sample. The results are shown in Figure 7 shown.

[0110] The experimental results show that compared with the treatment group using tobramycin alone, the conjugate A11@NO significantly helps tobramycin reduce the toxicity of the super biofilm environment to nematodes. Figure 7 As shown, in the treatment group using only MBC-level tobramycin, the survival rate of nematodes was only 10%-20%, while in the treatment group supplemented with A11@NO, the survival rate of nematodes was significantly improved. When 10μM A11@NO was used in combination with MBC-level tobramycin, the survival rate of nematodes reached nearly 60%.

[0111] The above embodiments are preferred implementation modes of the present invention, but the implementation modes of the present invention are not limited to the above embodiments. Any other changes, modifications, substitutions, combinations, and simplifications that do not deviate from the spirit and principles of the present invention should be equivalent replacement methods and are included in the protection scope of the present invention.

Claims

1. A conjugate of a bacterial messenger molecule c-di-GMP G-quadruplex inducer and an NO donor, characterized in that It has the structure shown in formula I or II: The number of substitutions of R1 on the benzene ring is 1, 2 or more. When the number of substitutions of R1 on the benzene ring exceeds one, the substituents R1 are the same or different; R1 is relatively independent of -H, -F, -Br, -NO2, -CH3, -NH2, -N(CH3)2, 4-methylpiperazine-1-yl, 4-morpholinyl, -OH or -OCH3; The number of NO donors on the benzene ring is 1, 2 or more. When the number exceeds 1, the NO donors are the same or different. The NO donors are all relatively independent and are one of the following structural fragments, wherein when R2 is an alkyl group, the number of C atoms is 1-3:

2. The conjugate of bacterial messenger molecule c-di-GMP G-quadruplex inducer and NO donor according to claim 1, characterized in that Has the following structure: The definitions of R1 and R2 therein are consistent with those of R1 and R2 in formula I and II.

3. The conjugate of bacterial messenger molecule c-di-GMP G-quadruplex inducer and NO donor according to claim 1, characterized in that Has the following structure:

4. A method for preparing a conjugate of a bacterial messenger molecule c-di-GMP G-quadruplex inducer and a NO donor according to any one of claims 1 to 3, characterized in that The following steps are involved: First, 2-methylbenzothiazole or 2-methylquinoline reacts with methyl iodide to obtain compound 4 or compound 6; compound 2 reacts with fatty amine R2-NH2 to obtain compound 5 by nucleophilic substitution reaction; Then, compound 4 or compound 6 reacts with compound 5 to produce a benzothiazole compound A or a quinoline compound B; Finally, A or B and NO gas react under high pressure to form a conjugate; The preparation route is as follows: The definitions of R1 and R2 are consistent with those of R1 and R2 in formula I and II, and -X is one of -Br, -Cl, -F, and -I.

5. The method for preparing the conjugate of bacterial messenger molecule c-di-GMP G-quadruplex inducer and NO donor according to claim 4, characterized in that The specific steps include: (1) Dissolve 2-methylbenzothiazole or 2-methylquinoline in a solvent, add iodomethane, and then heat under reflux for 12 to 18 hours under a nitrogen atmosphere. After the reaction is completed, compound 4 or compound 6 is obtained; (2) Compound 2 and fatty amine R2-NH2 are dissolved in a solvent, a catalyst is added, and then heated to react for 24 h to 48 h. After the reaction is completed, compound 5 is obtained; (3) Compound 4 or Compound 6 and Compound 5 are dissolved in a solvent, a catalyst is added, and then heated under reflux for reaction for 12 h to 16 h. After the reaction is completed, a benzothiazole compound A or a quinoline compound B is obtained; (4) using a solvent to completely dissolve compound A or B, adding the solution to a high pressure reactor, and reacting with NO at room temperature under a pressure of 1 to 10 MPa for 12 to 72 hours, to obtain a conjugate A@NO or B@NO after the reaction is completed.

6. The method for preparing the conjugate of bacterial messenger molecule c-di-GMP G-quadruplex inducer and NO donor according to claim 5, characterized in that: The solvent described in step (1) is at least one of acetonitrile, ethanol, DMF and toluene; The solvent described in step (2) is DMSO; The catalyst described in step (2) is copper powder or tetrabutylammonium bromide and potassium carbide; The temperature of the heating reaction in step (2) is 98-102°C; The solvent in step (3) is at least one of methanol and ethanol; The catalyst described in step (3) is piperidine or pyridine; The solvent described in step (4) is one or two of acetonitrile, methanol and ethanol.

7. The method for preparing the conjugate of bacterial messenger molecule c-di-GMP G-quadruplex inducer and NO donor according to claim 5, characterized in that: The molar ratio of 2-methylbenzothiazole or 2-methylquinoline to methyl iodide in step (1) is 1:1.05-1.5; When the catalyst in step (2) is copper powder, the molar ratio of the compound 2, the fatty amine and the copper powder in step (2) is 1:6-10:0.02-0.05; when the catalyst in step (2) is tetrabutylammonium bromide and potassium carbonate, the molar ratio of the compound 2, the fatty amine, the tetrabutylammonium bromide and potassium carbonate in step (2) is 1:5-6:0.1-0.5:0.5-1; The molar ratio of compound 4 (or compound 6), compound 5 and catalyst described in step (3) is 1:1.1-1.5:0.1-0.

5.

8. Use of the conjugate of the bacterial messenger molecule c-di-GMP G-quadruplex inducer and NO donor according to any one of claims 1 to 3 in the preparation of antibacterial biofilm drugs and as antibacterial adjuvants, especially in the preparation of Pseudomonas aeruginosa biofilm inhibitors.

9. Use of the conjugate of bacterial messenger molecule c-di-GMP G-quadruplex inducer and NO donor according to claim 8 in the preparation of antibacterial biofilm drugs and as antibacterial adjuvants, characterized in that: The antibacterial biofilm drug contains at least one of the conjugate of the bacterial messenger molecule c-di-GMP G-quadruplex inducer and NO donor, the pharmaceutically acceptable salt of the conjugate and the solvate of the conjugate.

10. Use of the conjugate of bacterial messenger molecule c-di-GMP G-quadruplex inducer and NO donor according to claim 7 in the preparation of antibacterial biofilm drugs and as antibacterial adjuvants, characterized in that: The application as an anti-biofilm bacteria adjuvant refers to the combined use of the conjugate and the antibiotic, wherein the concentration of the conjugate is greater than or equal to the effective concentration for removing biofilm, and the concentration of the antibiotic is greater than or equal to the minimum bactericidal concentration.